Porownywarka

Eloralintide vs Cagrilintide side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

EloralintideCagrilintide

Udostępnij porównanie peptydów

Wlasciwosc	Eloralintide	Cagrilintide
Kategoria	Redukcja masy	Redukcja masy
Znany tez jako	LY3841136	AM833, NN9838, CagriSema (combination)
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Phase 3 recruiting; investigational. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Investigational phase 3 program, mainly through CagriSema; source reports an NDA submitted in Dec 2025 with FDA decision expected in Q4 2026. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Obesity and overweight	Weight loss, appetite control, combination therapy
Jak dziala	Eloralintide is described as a selective amylin receptor agonist. In the supplied mechanism text, amylin/IAPP signaling involves receptor complexes formed by the calcitonin receptor with receptor-activity-modifying proteins, with activity in brainstem and hypothalamic regions involved in appetite control. The proposed effect is earlier satiety and reduced food intake. The source also states that lower nausea and vomiting versus injectable GLP-1 drugs was reported in Eloralintide trials, while lean-mass preservation remains unproven.	Cagrilintide is described as a long-acting amylin analog with activity across the amylin and calcitonin receptor family. The source reports signaling through amylin receptor complexes, including receptors formed by calcitonin receptors with RAMP proteins. Reported downstream effects include central satiety signaling, delayed gastric emptying, and moderation of meal-related glucagon increases. Mechanistic animal data in the source emphasize AMY1R and AMY3R pathways involving hindbrain regions such as the area postrema, nucleus of the solitary tract, and parabrachial nucleus. The molecule is described as a modified pramlintide-like 37-amino-acid analog with a fatty-diacid modification intended to extend exposure to about one week.
Typowe dawkowanie	Investigational study doses of 1-9 mg once weekly; no approved dose is established.	2.4 mg weekly · Once weekly
Dawkowanie z badań	1-9 mg once weekly in the Phase 2 study · Once weekly · 48 weeks · Subcutaneous injection	2.4 mg weekly · Once weekly · Long-term / chronic use expected · Subcutaneous injection once weekly
Typowy czas trwania	48 weeks in the Phase 2 study	Long-term / chronic use expected
Podanie	Subcutaneous injection	Subcutaneous injection once weekly
Timing	-	Any consistent time weekly With or without food
Poziom dowodów	Badania kliniczne	Badania kliniczne
Mozliwe skutki uboczne	Nausea (Source reports lower incidence than injectable GLP-1s and gives nausea at 8% in the Phase 1 summary.) Diarrhea Vomiting (Source gives vomiting at 4% in the Phase 1 summary.) +5 więcej Constipation Decreased appetite Abdominal discomfort Fatigue (Phase 2 topline summary describes fatigue among common mild-to-moderate adverse events.) Limited long-term safety data (Source states long-term safety and cardiovascular outcome results are not yet available.)	Nausea (Reported as common and usually temporary in the source.) Vomiting (Listed among reported gastrointestinal effects.) Diarrhea (Listed among reported gastrointestinal effects.) +8 więcej Constipation (Listed among reported gastrointestinal effects.) Abdominal pain (Reported in the source as a gastrointestinal adverse effect.) Injection site reactions (Reported in the source without additional severity detail.) Decreased appetite (Reported in the source; clinical relevance depends on study context.) Headache (Reported in the source without additional severity detail.) Dyspepsia (Reported in the source as a gastrointestinal symptom.) Gastrointestinal events in CagriSema trials (Source reports 79.6% affected, mostly mild to moderate.) Limited long-term safety data (Source notes ongoing trials and incomplete long-term safety characterization.)
Podsumowanie researchu	The supplied research summary reports a Phase 1 proof-of-concept trial published in 2026 by Eli Lilly that randomized 100 adults with obesity across five ascending dose groups. It describes dose-proportional pharmacokinetics and least-squares mean weight reductions from 2.6% to 11.3% at week 12, with nausea at 8% and vomiting at 4%. The source also reports Lilly topline Phase 2 results from November 2025 in 263 adults with obesity or overweight: at 48 weeks, all dose arms exceeded placebo, with mean weight loss ranging from about 9.5% at the lowest dose to 20.1% at 9 mg, compared with 0.4% on placebo. Other reported changes included waist circumference, blood pressure, lipid, and glycemic marker improvements. The source notes mild-to-moderate nausea and fatigue as common adverse events, and it cautions that full peer-reviewed Phase 2 data, head-to-head tirzepatide data, long-term safety, and cardiovascular outcome evidence were not yet available.	The supplied source describes cagrilintide as having controlled human evidence, including a 2021 phase 2 dose-finding trial in which once-weekly 4.5 mg cagrilintide was associated with about 10.8% mean body-weight loss over 26 weeks, compared with roughly 3% for placebo and about 9% for liraglutide 3.0 mg. The source also highlights phase 3 REDEFINE development for CagriSema in obesity and type 2 diabetes, with weight-loss results reported in the low-20% range for the combination. Gastrointestinal tolerability issues, especially nausea and vomiting, are described as prominent. As presented by the source, cagrilintide remains investigational rather than an approved standalone therapy.
Referencje	PubMed PR Newswire +2 więcej Eli Lilly Investor Relations Eli Lilly	Źródło Źródło +3 więcej Źródło Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Eloralintide

Cagrilintide

Kategoria

Redukcja masy

Znany tez jako

LY3841136

AM833, NN9838, CagriSema (combination)

Zatwierdzony przez FDA

Nie

Status kliniczny

Phase 3 recruiting; investigational.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Investigational phase 3 program, mainly through CagriSema; source reports an NDA submitted in Dec 2025 with FDA decision expected in Q4 2026.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Obesity and overweight

Weight loss, appetite control, combination therapy

Jak dziala

Eloralintide is described as a selective amylin receptor agonist. In the supplied mechanism text, amylin/IAPP signaling involves receptor complexes formed by the calcitonin receptor with receptor-activity-modifying proteins, with activity in brainstem and hypothalamic regions involved in appetite control. The proposed effect is earlier satiety and reduced food intake. The source also states that lower nausea and vomiting versus injectable GLP-1 drugs was reported in Eloralintide trials, while lean-mass preservation remains unproven.

Cagrilintide is described as a long-acting amylin analog with activity across the amylin and calcitonin receptor family. The source reports signaling through amylin receptor complexes, including receptors formed by calcitonin receptors with RAMP proteins. Reported downstream effects include central satiety signaling, delayed gastric emptying, and moderation of meal-related glucagon increases. Mechanistic animal data in the source emphasize AMY1R and AMY3R pathways involving hindbrain regions such as the area postrema, nucleus of the solitary tract, and parabrachial nucleus. The molecule is described as a modified pramlintide-like 37-amino-acid analog with a fatty-diacid modification intended to extend exposure to about one week.

Typowe dawkowanie

Investigational study doses of 1-9 mg once weekly; no approved dose is established.

2.4 mg weekly · Once weekly

Dawkowanie z badań

1-9 mg once weekly in the Phase 2 study · Once weekly · 48 weeks · Subcutaneous injection

2.4 mg weekly · Once weekly · Long-term / chronic use expected · Subcutaneous injection once weekly

Typowy czas trwania

48 weeks in the Phase 2 study

Long-term / chronic use expected

Podanie

Subcutaneous injection

Subcutaneous injection once weekly

Timing

Any consistent time weekly

With or without food

Poziom dowodów

Badania kliniczne

Mozliwe skutki uboczne

Nausea (Source reports lower incidence than injectable GLP-1s and gives nausea at 8% in the Phase 1 summary.)
Diarrhea
Vomiting (Source gives vomiting at 4% in the Phase 1 summary.)

+5 więcej

Constipation
Decreased appetite
Abdominal discomfort
Fatigue (Phase 2 topline summary describes fatigue among common mild-to-moderate adverse events.)
Limited long-term safety data (Source states long-term safety and cardiovascular outcome results are not yet available.)

Nausea (Reported as common and usually temporary in the source.)
Vomiting (Listed among reported gastrointestinal effects.)
Diarrhea (Listed among reported gastrointestinal effects.)

+8 więcej

Constipation (Listed among reported gastrointestinal effects.)
Abdominal pain (Reported in the source as a gastrointestinal adverse effect.)
Injection site reactions (Reported in the source without additional severity detail.)
Decreased appetite (Reported in the source; clinical relevance depends on study context.)
Headache (Reported in the source without additional severity detail.)
Dyspepsia (Reported in the source as a gastrointestinal symptom.)
Gastrointestinal events in CagriSema trials (Source reports 79.6% affected, mostly mild to moderate.)
Limited long-term safety data (Source notes ongoing trials and incomplete long-term safety characterization.)

Podsumowanie researchu

The supplied research summary reports a Phase 1 proof-of-concept trial published in 2026 by Eli Lilly that randomized 100 adults with obesity across five ascending dose groups. It describes dose-proportional pharmacokinetics and least-squares mean weight reductions from 2.6% to 11.3% at week 12, with nausea at 8% and vomiting at 4%. The source also reports Lilly topline Phase 2 results from November 2025 in 263 adults with obesity or overweight: at 48 weeks, all dose arms exceeded placebo, with mean weight loss ranging from about 9.5% at the lowest dose to 20.1% at 9 mg, compared with 0.4% on placebo. Other reported changes included waist circumference, blood pressure, lipid, and glycemic marker improvements. The source notes mild-to-moderate nausea and fatigue as common adverse events, and it cautions that full peer-reviewed Phase 2 data, head-to-head tirzepatide data, long-term safety, and cardiovascular outcome evidence were not yet available.

The supplied source describes cagrilintide as having controlled human evidence, including a 2021 phase 2 dose-finding trial in which once-weekly 4.5 mg cagrilintide was associated with about 10.8% mean body-weight loss over 26 weeks, compared with roughly 3% for placebo and about 9% for liraglutide 3.0 mg. The source also highlights phase 3 REDEFINE development for CagriSema in obesity and type 2 diabetes, with weight-loss results reported in the low-20% range for the combination. Gastrointestinal tolerability issues, especially nausea and vomiting, are described as prominent. As presented by the source, cagrilintide remains investigational rather than an approved standalone therapy.

Referencje

PubMed PR Newswire

+2 więcej

Eli Lilly Investor Relations Eli Lilly

Źródło Źródło

+3 więcej

Źródło Źródło Źródło

Pełny profil

Zobacz szczegóły